Aylie Widjaja, managing director at Exeltis Indonesia, shares her excitement about developing the company’s footprint in Indonesia, making it a manufacturing hub for Asia, and highlights the challenges in navigating the public market.
How do you see the Indonesian healthcare landscape evolving?
"We have to give better options to patients to have more affordable and quality medicines through creating domestic manufacturing capabilities in the country and offer differentiated products."
Marlia Hayati and Joey Romana, President Director and Vice President Director at PT Darya-Varia Laboratoria, share insights about the company’s strong brand equity and pioneering manufacturing strategy. In 2016, the…
Haris Izmee, director at GE Healthcare Indonesia, explains the strong commitment of the company towards improving access, affordability and quality and highlights the company’s significant investments in internal capabilities and…
Evie Yulin, biopharma country director at Merck Indonesia, speaks towards the meaning of innovation in emerging countries and how the company engages in innovation beyond products. Since 2012, Merck has been…
With a market value of USD 5.2 billion, Kalbe Farma has consolidated into Indonesia’s undisputed national pharma champion and has established a footprint in many ASEAN countries as well as…
The latest from the pharma industry in Southeast Asia, including underwhelming results from Kalbe Pharma, Indonesia’s largest pharma company; Novavax’s vaccine manufacturing plans in the Philippines; the promising future of…
The latest pharma news from the Asia-Pacific region, including upcoming IPOs for Prestige Biopharma and HH&L Acquisition; logistics challenges for COVID-19 vaccine distributors; and Moderna’s CMO-based vaccine manufacturing strategy in…
See our Cookie Privacy Policy Here